Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study.

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

While experts welcomed Mounjaro's launch, they stressed the importance of responsible prescribing to prevent misuse of the drug used for the treatment of type 2 diabetes and obesity.